Company / Revenue
Haemonetics Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$1.4B
FY2024
5-year range
$993.2M / $1.4B
FY2020-FY2024
Trend
+4.0%
vs FY2023
Sector context
#93 of 150
Health Care
What the data says
At $1.4B, Haemonetics's revenue ranks #93 of 150 in the Health Care sector. Revenue has increased for 4 consecutive years, from $225M in FY2017 to $1.4B in FY2024.
Based on SEC 10-K filings.
$1.4B in FY2024 with a 3-year CAGR of +11.1%.
Improved from $1.2B to $1.4B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +11.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#93 of 150 in Health CareTop 62% of 150This company $1.4B Sector average $19.6B
▼
-93.1% below sector average
Key checks
Key Insights
- Haemonetics's revenue has grown for 3 consecutive years.
- 3-year CAGR of +11.1%, indicating consistent growth.
- In FY2024, revenue increased 4.0% year-over-year.
- Ranks #93 out of 150 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.4B | +4.0% |
| FY2023 | $1.3B | +12.0% |
| FY2022 | $1.2B | +17.7% |
| FY2021 | $993.2M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $225.4M | -74.6% |
| FY2016 | $886.1M | -2.5% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026